Labcorp Holdings earned an RS Rating Upgrade. In 2025, it has announced a quarterly cash dividend. ORG Partners LLC acquired 2,298 shares. While the
stock price looks inconsistent with the financials, Q1 2024 earnings call suggests solid performance. The firm participated in the J.P. Morgan Healthcare Conference and is considering a boost in mpox testing capacity. A 52-week high stock price at $238.93 was achieved amid robust growth. They declared another
quarterly dividend, issued senior notes, and announced a winning bid for Select Assets of Invitae. The
acquisition of BioReference Health's diagnostics business signifies expansion, while winning a bid from Invitae offers a strategic edge. Despite EPS missing expectations in Q3 2024, Labcorp announced increase in revenue guidance. Labcorp finalized acquisition of Select Assets of Invitae signaling growth and expansion strategy. However, the firm's high debt and the CEO's compensation package could be concerning. Labcorp's acquisition of Invitae for $239m, demonstrates bold strategic moves, while new research on
precision diagnostics offers promise. Notably, it has completed spin-off of Fortrea and made strategic partnerships.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 05 Nov 2014 08:00:00 GMT to Sat, 11 Jan 2025 09:05:45 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 5
